* Spruce Biosciences Inc SPRB.OQ SPRB.O is expected
to show a
fall in quarterly revenue when it reports results on November
11 (estimated) for the period ending September 30 2024
* The South San Francisco California-based company is
expected to
report a 51.4% decrease in revenue to $1.494 million from $3.07
million a year ago, according to the mean estimate from 4
analysts, based on LSEG data.
* LSEG's mean analyst estimate for Spruce Biosciences Inc
is for
a loss of 24 cents per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Spruce
Biosciences Inc is $2.50, above its last closing price
of $0.55.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jan. 1 0001 -0.32 -0.32 -0.22 Beat 31.4
Mar. 31 0001 -0.29 -0.29 -0.28 Beat 3.2
Dec. 31 2023 -0.39 -0.39 -0.24 Beat 37.8
Sep. 30 2023 -0.36 -0.35 -0.30 Beat 15.1
Jun. -0.39 -0.39 -0.32 Beat 18.4
30 2023
Mar. 31 2023 -0.33 -0.36 -0.40 Missed -10.4
Dec. 31 2022 -0.56 -0.53 -0.47 Beat 11.3
Sep. 30 2022 -0.54 -0.53 -0.48 Beat 10.3
This summary was machine generated November 8 at 15:53 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)